Novel experimental therapies for treatment of pulmonary arterial hypertension

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Pulmonary arterial hypertension (PAH) is a progressive and devastating disease characterized by pulmonary artery vasoconstriction and vascular remodeling leading to vascular rarefaction with elevation of pulmonary arterial pressures and pulmonary vascular resistance. Often PAH will cause death from right heart failure. Current PAH-targeted therapies improve functional capacity, pulmonary hemodynamics and reduce hospitalization. Nevertheless, today PAH still remains incurable and is often refractory to medical therapy, underscoring the need for further research. Over the last three decades, PAH has evolved from a disease of unknown pathogenesis devoid of effective therapy to a condition whose cellular, genetic and molecular underpinnings are unfolding. This article provides an update on current knowledge and summarizes the progression in recent advances in pharmacological therapy in PAH.

Original languageEnglish (US)
Pages (from-to)817-857
Number of pages41
JournalJournal of Experimental Pharmacology
StatePublished - 2021


  • Animal models
  • Clinical trials
  • Investigational drugs
  • New drug targets
  • Pulmonary hypertension
  • Toxicity
  • Vascular remodelling

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Novel experimental therapies for treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this